Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study

Xenon Pharmaceuticals (XENE) presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures at the American Academy of Neurology Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Xenon is also presenting data at the AAN meeting that reinforce the significant opportunity for azetukalner in epilepsy, including 48-month data from the ongoing X-TOLE open-label extension, OLE, study, as well as real-world data reinforcing the potential value that no-titration options like azetukalner would bring to epilepsy management. Azetukalner, AZK, is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.